Skip to main content

Allergic Conjunctivitis

68
Pipeline Programs
19
Companies
50
Clinical Trials
3 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
17
0
27
22
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 77 programs with unclassified modality

On Market (3)

Approved therapies currently available

Bausch + Lomb
CHILDREN'S ALAWAYApproved
ketotifen fumarate
Bausch + Lomb
ophthalmic2006
Bausch + Lomb
ALAWAYApproved
ketotifen fumarate
Bausch + Lomb
ophthalmic2006
OLOPATADINE HYDROCHLORIDEApproved
olopatadine
Unknown Company
ophthalmic2015

Competitive Landscape

19 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
21 programs
1
3
7
10
AL-4943APhase 41 trial
Dexamethasone 0.1% ophthalmic suspensionPhase 41 trial
OlopatadinePhase 41 trial
Olopatadine 0.1%Phase 41 trial
Olopatadine HCl ophthalmic solution, 0.1%Phase 41 trial
+16 more programs
Active Trials
NCT01326858Completed50Est. Jun 2011
NCT01001091Completed312Est. Apr 2010
NCT02079649Completed224Est. Jul 2014
+18 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
14 programs
2
9
2
BepotastinePhase 41 trial
Refresh Tears 0.5% Lubricant Eye DropsPhase 41 trial
BeprevePhase 31 trial
BeprevePhase 31 trial
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic SolutionPhase 31 trial
+9 more programs
Active Trials
NCT01339507Completed25Est. Jun 2011
NCT00375596Withdrawn0
NCT01174823Completed245Est. Dec 2010
+12 more trials
Bausch + Lomb
Bausch + LombNJ - Bridgewater
13 programs
2
8
2
BepotastinePhase 4
Refresh Tears 0.5% Lubricant Eye DropsPhase 4
BeprevePhase 3
BeprevePhase 3
BromfenacPhase 3
+8 more programs
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
alacaftadine and naphazoline HCl & pheniramine maleatePhase 41 trial
AGN-229666Phase 21 trial
Active Trials
NCT01754766Completed90Est. Feb 2013
NCT01390961Unknown48Est. Jan 2012
MSD
MSDIreland - Ballydine
2 programs
2
ElestatPhase 4Small Molecule1 trial
epinastine HCL and olopatadine HCLPhase 41 trial
Active Trials
NCT00534794Completed79
NCT00489398Withdrawn25Est. Dec 2008
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
2
ElestatPhase 4Small Molecule
epinastine HCL and olopatadine HCLPhase 4
Aldeyra Therapeutics
Aldeyra TherapeuticsMA - Lexington
5 programs
1
1
3
Reproxalap Ophthalmic SolutionPhase 31 trial
Reproxalap Ophthalmic SolutionPhase 31 trial
Reproxalap Ophthalmic SolutionPhase 31 trial
NS2 Ophthalmic DropsPhase 21 trial
Reproxalap Ophthalmic SolutionPhase 1/21 trial
Active Trials
NCT03660878Completed52Est. Nov 2019
NCT02578914Completed100Est. Dec 2015
NCT04207736Completed95Est. Feb 2021
+2 more trials
Telios Pharma
Telios PharmaCA - Redwood City
4 programs
4
TL-925Phase 21 trial
TL-925Phase 21 trial
TL-925Phase 21 trial
TL-925Phase 21 trial
Active Trials
NCT06153342Unknown70Est. Jan 2024
NCT07220408Recruiting60Est. Feb 2026
NCT06293820Completed80Est. May 2024
+1 more trials
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
2 programs
2
Active Comparator EBI-005 5 mg/mLPhase 2
ST266Phase 2
Eleven Therapeutics
Eleven TherapeuticsIsrael - Tel Aviv
1 program
1
Active Comparator EBI-005 5 mg/mLPhase 21 trial
Active Trials
NCT02082899Completed150Est. Jul 2014
Noveome Biotherapeutics
1 program
1
ST266Phase 21 trial
Active Trials
NCT02978183Completed70Est. Nov 2017
Faes Farma
Faes FarmaSpain - Leioa
3 programs
Bilastine 0.2%PHASE_21 trial
BilastinePHASE_31 trial
Bilastine Ophthalmic Solution 0.6%PHASE_31 trial
Active Trials
NCT03231969Completed121Est. Oct 2017
NCT04810390Completed59Est. Nov 2022
NCT03479307Completed228Est. Aug 2018
Santen
SantenCA - Emeryville
2 programs
DE-114 ophthalmic solutionPHASE_31 trial
DE-114 ophthalmic solutionPHASE_31 trial
Active Trials
NCT01363700Completed87
NCT01363713Completed130
Regeneron
RegeneronTARRYTOWN, NY
2 programs
REGN5713PHASE_31 trial
REGN5713PHASE_31 trial
Active Trials
NCT06602739Completed54Est. Aug 2025
NCT07309432Recruiting350Est. Jun 2027
Merck & Co.
Merck & Co.RAHWAY, NJ
2 programs
ElestatPHASE_4Small Molecule
epinastine HCL and olopatadine HCLPHASE_4
Marinomed Biotech
Marinomed BiotechAustria - Korneuburg
1 program
Eye Drops, Solution in Single-Dose ContainerPHASE_21 trial
Active Trials
NCT04532710Completed64Est. May 2021
Takeda
TakedaTOKYO, Japan
1 program
LifitegrastPHASE_21 trial
Active Trials
NCT00882687Completed60Est. May 2009
Vanda Pharmaceuticals
Vanda PharmaceuticalsWASHINGTON, DC
1 program
VSJ-110PHASE_21 trial
Active Trials
NCT04622345Completed47Est. Jun 2021
Thea Pharma
Thea PharmaMA - Waltham
1 program
NAABAK eyedropsPHASE_41 trial
Active Trials
NCT01203540CompletedEst. Jan 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Bausch HealthBromfenac
AlconOlopatadine HCl ophthalmic solution, 0.1%
AlconOlopatadine hydrochloride ophthalmic solution, 0.2%
AbbViealacaftadine and naphazoline HCl & pheniramine maleate
Bausch HealthRefresh Tears 0.5% Lubricant Eye Drops
AlconOlopatadine Hydrochloride Ophthalmic Solution, 0.2%
Bausch HealthBepotastine
AlconOlopatadine hydrochloride, 0.1% ophthalmic solution
Thea PharmaNAABAK eyedrops
AlconAL-4943A
AlconOlopatadine hydrochloride ophthalmic solution, 0.2%
AlconDexamethasone 0.1% ophthalmic suspension
AlconOlopatadine hydrochloride ophthalmic solution 0.1%
AlconOlopatadine 0.1%
MSDElestat

Showing 15 of 47 trials with date data

Clinical Trials (50)

Total enrollment: 8,720 patients across 50 trials

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

Start: Aug 2021Est. completion: Dec 202277 patients
Phase 4Completed
NCT02251613AlconOlopatadine HCl ophthalmic solution, 0.1%

Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan

Start: Dec 2013Est. completion: Jan 201450 patients
Phase 4Completed
NCT01697969AlconOlopatadine hydrochloride ophthalmic solution, 0.2%

Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients

Start: Sep 2012Est. completion: Jul 201317 patients
Phase 4Completed
NCT01390961AbbViealacaftadine and naphazoline HCl & pheniramine maleate

Comparison of Tolerability Between Two Allergy Drops

Start: Aug 2011Est. completion: Jan 201248 patients
Phase 4Unknown
NCT01346371Bausch HealthRefresh Tears 0.5% Lubricant Eye Drops

The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer

Start: May 2011Est. completion: Sep 201240 patients
Phase 4Completed
NCT01272089AlconOlopatadine Hydrochloride Ophthalmic Solution, 0.2%

A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

Start: May 2011Est. completion: Dec 2011300 patients
Phase 4Completed

Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses

Start: May 2011Est. completion: Nov 201124 patients
Phase 4Unknown
NCT01282138AlconOlopatadine hydrochloride, 0.1% ophthalmic solution

Assessment of Alcon's Ocular Image Quantification System

Start: Dec 2010Est. completion: Mar 201113 patients
Phase 4Completed
NCT01203540Thea PharmaNAABAK eyedrops

Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients

Start: Oct 2010Est. completion: Jan 2011
Phase 4Completed

Patient Perception Study for AL-4943A

Start: Sep 2010Est. completion: Oct 201147 patients
Phase 4Completed
NCT01159769AlconOlopatadine hydrochloride ophthalmic solution, 0.2%

Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

Start: Jun 2010Est. completion: Aug 2010215 patients
Phase 4Completed
NCT01119287AlconDexamethasone 0.1% ophthalmic suspension

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

Start: Mar 2010Est. completion: Sep 2010180 patients
Phase 4Completed
NCT01109485AlconOlopatadine hydrochloride ophthalmic solution 0.1%

Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients

Start: Mar 2010Est. completion: Jul 201142 patients
Phase 4Completed
NCT00818805AlconOlopatadine 0.1%

Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)

Start: Jul 200850 patients
Phase 4Completed

Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis

Start: Oct 200779 patients
Phase 4Completed
NCT00489398MSDepinastine HCL and olopatadine HCL

Comparison of CL Wear Between Two Allergy Drops

Start: Jul 2007Est. completion: Dec 200825 patients
Phase 4Withdrawn
NCT00389025AlconOlopatadine

Mast-Cell Stabilizing Effects of Olopatadine

Start: Oct 200624 patients
Phase 4Completed
NCT01363700SantenDE-114 ophthalmic solution

Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

87 patients
Phase 3Completed
NCT01363713SantenDE-114 ophthalmic solution

A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

130 patients
Phase 3Completed

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

Start: Jan 2026Est. completion: Jun 2027350 patients
Phase 3Recruiting

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

Start: Nov 2024Est. completion: Aug 202554 patients
Phase 3Completed
NCT05815758Bausch HealthBrimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

Start: Apr 2023Est. completion: Sep 2023512 patients
Phase 3Completed
NCT05579730Bausch HealthBrimonidine tartrate 0.025%/ketotifen fumarate 0.035%

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Start: Oct 2022Est. completion: Jul 2023188 patients
Phase 3Completed
NCT05234554Aldeyra TherapeuticsReproxalap Ophthalmic Solution

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Start: Jan 2022Est. completion: Apr 2023131 patients
Phase 3Completed

Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

Start: Mar 2021Est. completion: Nov 202259 patients
Phase 3Completed
NCT04207736Aldeyra TherapeuticsReproxalap Ophthalmic Solution

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Start: Dec 2019Est. completion: Feb 202195 patients
Phase 3Completed
NCT03479307Faes FarmaBilastine Ophthalmic Solution 0.6%

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

Start: Apr 2018Est. completion: Aug 2018228 patients
Phase 3Completed

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

Start: Apr 2018Est. completion: Apr 201865 patients
Phase 3Completed
NCT03494504Aldeyra TherapeuticsReproxalap Ophthalmic Solution

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Start: Mar 2018Est. completion: Nov 2018318 patients
Phase 3Completed
NCT02322216AlconOlopatadine Hydrochloride Ophthalmic Solution 0.2%

Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects

Start: Dec 2014Est. completion: Oct 2015383 patients
Phase 3Completed
NCT01743027AlconAL-4943A ophthalmic solution

Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

Start: Jan 2013Est. completion: Jul 2013902 patients
Phase 3Completed
NCT01698814AlconAL-4943A Ophthalmic Solution

A Six-Week Safety Study of an Investigational Ophthalmic Solution

Start: Oct 2012Est. completion: Jan 2013518 patients
Phase 3Completed
NCT01479374AlconAL-4943A ophthalmic solution

Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model

Start: Jan 2012Est. completion: Mar 2012397 patients
Phase 3Completed

Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers

Start: Jul 2010Est. completion: Oct 2010534 patients
Phase 3Completed
NCT01037179AlconOlopatadine Hydrochloride Ophthalmic Solution, 0.2%

An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

Start: Feb 2010Est. completion: May 2010110 patients
Phase 3Completed
NCT00770133Bausch HealthKetotifen/naphazoline

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

Start: Feb 2010Est. completion: Jun 2010141 patients
Phase 3Completed
NCT00987272AlconOlopatadine Hydrochloride Ophthalmic Solution, 0.2%

Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects

Start: Oct 2009Est. completion: Nov 2009267 patients
Phase 3Completed
NCT00769886Bausch HealthKetotifen/naphazoline

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

Start: Oct 2008Est. completion: Jun 2009144 patients
Phase 3Completed

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

Start: Oct 2007Est. completion: Jun 2008130 patients
Phase 3Completed

Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

Start: Oct 2007861 patients
Phase 3Completed

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

Start: Nov 2006Est. completion: Aug 200790 patients
Phase 3Completed
NCT00331500AlconOlopatadine Hydrochloride Ophthalmic Solution, 0.2%

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

Start: Apr 2006Est. completion: Jul 2006287 patients
Phase 3Completed
NCT00375596Bausch HealthKetotifen/vasoconstrictor

A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

0
Phase 2Withdrawn

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

Start: Oct 2025Est. completion: Feb 202660 patients
Phase 2Recruiting

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

Start: Oct 2024Est. completion: Dec 202466 patients
Phase 2Recruiting

A Study Of TL-925 For The Treatment of AC

Start: Apr 2024Est. completion: May 202480 patients
Phase 2Completed

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Start: Nov 2023Est. completion: Jan 202470 patients
Phase 2Unknown

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

Start: Nov 2020Est. completion: Jun 202147 patients
Phase 2Completed
NCT04532710Marinomed BiotechEye Drops, Solution in Single-Dose Container

Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis

Start: Aug 2020Est. completion: May 202164 patients
Phase 2Completed
NCT03231969Faes FarmaBilastine 0.2%

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Start: Jul 2017Est. completion: Oct 2017121 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

27 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 8,720 patients
19 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.